Search PubMed⌕ Search

Biomedical subjects

N A Boon

Publications and source records attributed to N A Boon.

77 records · Page 5Linked to original sources

An in vivo study of cation transport in essential hypertension.

In order to study cation transport in vivo the changes in plasma and red cell rubidium concentrations were measured following an oral load of rubidium chloride. Eight patients receiving short-term digoxin therapy, 10 patients with chronic renal failure and 22 patients with untreated essential hypertension were studied, and the findings were compared with those in healthy control subjects matched for age, sex, race, obesity index, and plasma and red cell potassium concentrations. In patients receiving short-term digoxin therapy, and in patients with chronic renal failure, the increases in plasma rubidium concentrations after the oral load of rubidium chloride were significantly enhanced and the increases in red cell rubidium concentrations were significantly attenuated. These findings are consistent with a generalized reduction in Na+, K+-ATPase activity in vivo. In contrast, in patients with untreated essential hypertension the increases in both plasma and red cell rubidium concentrations following the oral load were significantly enhanced. These data do not support the hypothesis that essential hypertension is associated with reduced Na+, K+-ATPase activity in vivo, at least in the red cell.

Adult↗

A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]-dihydroergocryptine.

The binding characteristics of [3H]-yohimbine on intact human platelets were investigated and compared to those of [3H]-dihydroergocryptine. A significant correlation (r = 0.92, P less than 0.01, n = 7) was observed between the inhibition of [3H]-yohimbine binding and of noradrenaline-induced platelet aggregation, indicating that [3H]-yohimbine binds to the alpha 2-adrenoreceptor responsible for noradrenaline-induced platelet aggregation. The binding capacity of [3H]-yohimbine in 20 young male volunteers was 39 +/- 2.2 fmol/10(8) platelets (mean +/- s.e.m.). This is considerably lower than the binding capacity of [3H]-dihydroergocryptine previously reported. Simultaneous analysis of [3H]-yohimbine and [3H]-dihydroergocryptine binding in 10 subjects showed a significantly lower binding capacity for [3H]-yohimbine (P less than 0.001, paired t-test). This difference was not present in every subject, and was consistent within individuals on repeated testing. Possible causes of this difference in radioligand binding are discussed.

Adult↗

Incidence and significance of rising blood acetate levels during hemodialysis.

Recent work suggests that rising arterial acetate levels occur in some patients undergoing hemodialysis and that they may be responsible for some dialysis problems, particularly cardiovascular instability. Blood acetate levels and acetate flux rates have been determined in 20 adult and 4 pediatric patients during hemodialysis as well as in 4 patients with combined renal and hepatic failure. Rising acetate levels occurred in 25% of the adult patients, although they were stable in the children and the patients with renal and hepatic failure. The occurrence of hypotension during dialysis was unrelated to a high blood acetate level.

Acetates↗